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Background: Radium-223 dichloride is an alpha emitter approved for metastatic castration-
resistant prostate cancer (mCRPC). Unfortunately, little data are available on the prognostic 
factors during radium-223-based therapy.
Patients and methods: Patients with histologically confirmed progressive CRPC with two 
or more bone metastases and symptomatic disease were eligible. Previous therapy with a novel 
hormonal therapy was allowed. The patients received six intravenous injections of radium-223 
every 4 weeks. A visual analog scale (VAS) was adopted to evaluate patients’ basal pain.
Results: A total of 25 patients were evaluated. Of these, 6 (24%) reported VAS ,4. After a 
median follow-up of 8 months, all patients died with a median overall survival of 8.3 months 
(95% CI: 5.2–11.8 months), 12.6 months in the patients with VAS ,4 vs 6.6 months in the 
patients with VAS $4 (P=0.03).
Conclusion: The present study suggests that VAS could be prognostic of the survival of 
mCRPC treated with radium-223 irrespective of the limitations of a small number of patients 
and the retrospective nature of the data.
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Background
Prostate cancer is one of the most frequently occurring solid tumors worldwide.1 
Localized prostate cancer is generally treated with surgery or radiotherapy; unfortunately, 
in most patients, disease recurred with metastases overall in the bone sites. In fact, it 
was estimated that bone metastases are reported in ~90% of metastatic prostate cancer 
cases.2 In addition, bone metastases may be associated with significant morbidity and 
mortality (eg, pain, spinal fracture, and cord compression), impairing quality of life.2–5 
Therefore, different bone-targeted agents, including bisphosphonates and denosumab, 
have been developed.2–5 Radium-223 dichloride is an alpha emitter that is selectively 
incorporated in the bone matrix at sites of active mineralization via osteoblasts.6 
In the ALSYMPCA (ALpharadin in SYMPtomatic Prostate CAncer) Phase III trial, 
radium-223 showed an overall survival (OS) benefit in patients with castration-resistant 
prostate cancer (CRPC) and symptomatic bone metastases.6 In 2013, radium-223 was 
approved by the US Food and Drug Administration (FDA) for the treatment of patients 
with CRPC, symptomatic bone metastases, and no known visceral metastatic disease. 
Unfortunately, little data are available on the predictive factors of response to radium-223-
based therapy. The visual analog scale (VAS) for pain is a unidimensional measurement 
of pain intensity that is widely used in medicine.7 Several reports have demonstrated 
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that pain is a  statistically significant predictor of OS in men 
with metastatic CRPC.8,9 Therefore, the aim of this report is 
to verify whether the basal pain measured using the VAS for 
pain before radium-223-based therapy is related to its efficacy.
Patients and methods
inclusion criteria
This is a retrospective study of a cohort of patients treated with 
radium-223 in our single center enrollment. The patients were 
evaluated if they had histologically confirmed, progressive 
CRPC with two or more bone metastases detected by skeletal 
scintigraphy and no known visceral metastases. The presence 
of castration-resistant disease was defined as a serum testos-
terone level of 50 ng/dL or less (#2.0 nmol/L) after bilateral 
orchiectomy or during treatment consisting of androgen-
ablation therapy with a luteinizing hormone-releasing hormone 
agonist. Patients who had received docetaxel, abiraterone, or 
enzalutamide were enrolled. The patients were required to have 
symptomatic disease with the regular use of analgesic medica-
tion or treatment with external beam radiation therapy required 
for cancer-related bone pain within the previous 12 weeks. 
Additional eligibility criteria included evidence of progressively 
increasing prostate-specific antigen (PSA) values (two consecu-
tive increases over the previous reference value) or radiographic 
evidence of disease progression, and adequate hematological, 
renal, and hepatic function. Additional exclusion criteria were 
previous hemibody external radiotherapy, the presence of 
visceral metastases, and imminent or established spinal cord 
compression. All patients provided written informed consent. 
This study was approved by the local ethics committee of the 
IRCCS CROB, Referral Cancer Center of Basilicata Hospital.
Treatment plan and assessment
The patients received six intravenous injections of radium-
223 (at a dose of 50 kBq/kg of body weight); each injection 
was administered every 4 weeks. Safety was evaluated on 
day 15 of cycle 1 and on day 1 of each subsequent cycle. 
Laboratory tests, red blood cell, white blood cell, and platelet 
counts, and a comprehensive screening were performed 
at baseline. Efficacy assessments included survival status, 
clinically evaluated symptomatic skeletal events, and total 
ALP and PSA concentrations. Radiological investigations 
included chest, abdominal, and pelvic CT or MRI and bone 
scans at basal and at the end of six injections and after every 
3 months or sooner if clinically indicated.
Statistical analysis
VAS was recorded at the time of initiation and at the end 
of radium-223 treatment. The primary end point of this 
retrospective study was OS, defined as the time from the 
initiation of radium-223 to the date of death, regardless of 
cause. Secondary end points included the percentage of 
patients with an ALP reduction .30% from the basal value 
and the radiological response as evaluated according to 
Response Evaluation Criteria In Solid Tumors 1.1 criteria. 
Differences in the categorized variables were assessed using 
Fisher’s exact test. For the continuous variables, Student’s 
t-test or Mann–Whitney U tests were used to compare the 
groups. Kaplan–Meier survival curves were calculated and 
compared using the log-rank test. P-values ,0.05 were 
considered to indicate statistical significance. All analyses 
were conducted using Stata software.
Results
From November 2014 through March 2017, a total of 
25 patients were treated with radium-223. Of these, 6 (24%) 
reported VAS ,4 at baseline evaluation. Among these, none 
had a total ALP .220 U/L. In addition, none used opioids 
and this subgroup had less metastatic tumor burden as shown 
by the extent of disease and the number of metastatic sites. 
A total of 17 (68%) of the 25 patients received all six injec-
tions of radium-223. The median number of injections was 
six for the subgroup with VAS ,4 and five for the others. 
Baseline clinical characteristics of all of the men are reported 
in Table 1. After a median follow-up of 8 months, all of the 
patients died. They had a median OS of 8.3 months (95% 
CI: 5.2–11.8 months), 12.6 months in patients with VAS ,4 
vs 6.6 months in those with VAS $4 (P=0.03; Figure 1). 
In addition, data on the secondary end points are reported 
in Table 2. After adjusting for clinical covariates (total ALP 
level, Eastern Cooperative Oncology Group performance 
status, lines of therapies, and extent of disease), VAS ,4 
remained a prognostic factor of survival (HR=0.32, 95% 
CI: 0.20–0.95, P=0.04). Finally, data on basal VAS and its 
modification after radium-223 are shown in Figure 2.
Discussion
The randomized ALSYMPCA Phase III trial compared 
radium-223 efficacy vs placebo in patients with CRPC and 
symptomatic bone metastases.6 This study included only 
patients with disease progression during docetaxel treatment 
or those who were unfit to receive chemotherapy (43% of 
the enrolled men). In the updated analysis, the median OS 
was 14.9 months in the radium-223 group and 11.3 months 
in the placebo group. In our study, we observed a median 
OS of 8.3 months for radium-223, which was lower than 
that observed in the ALSYMPCA study. However, we also 
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Median (range) [year] 78 (58–88) 76 (64–80) 78 (58–88)
Total aLP [no (%)]
,220 u/L 12 (48%) 6 (100%) 6 (31.5%)
$220 u/L 13 (42%) 0 13 (68.4%)
Gleason score
,8 12 (48%) 2 (33.3%) 10 (55.5%)
$8 12 (48%) 4 (66.7%) 8 (42.1%)
Lines of therapy
1 20 (80%) 6 (100%) 14 (73.7%)
2 17 (68%) 5 (83.3%) 12 (63.1%)
3 9 (36%) 3 (50%) 6 (31.5%)
4 6 (24%) 2 (33.3%) 4 (21%)
Kind of drugs [no (%)]
Docetaxel 17 (68%) 4 (66.7%) 13 (68.4%)
novel hormonal therapy 16 (64%) 2 (33.3%) 14 (77.7%)
Cabazitaxel 8 (32%) 2 (33.3%) 6 (31.5%)
Other 7 (28%) 1 (16.7%) 6 (31.5%)
ECOG performance status score [no (%)]
#2 22 (88%) 6 (100%) 16 (84.3%)
.2 3 (12%) 0 3 (15.7%)
VaS for pain (median) 5 2 6
Pain therapy
no opioid use 14 (56%) 6 (100%) 8 (42.1%)
Opioid use 11 (44%) 0 11 (57.9%)
Extent of disease [no (%)]
,6 metastases 1 (4%) 0 1 (5.3%)
6–20 metastases 15 (60%) 4 (66.7%) 11 (57.9%)
.20 metastases 8 (32%) 2 (33.3%) 6 (31.5%)
Superscan 1 (4%) 0 1 (5.3%)
External beam radiation therapy within 12 weeks [no (%)]
Yes 4 (16%) 1 (16.7%) 3 (15.7%)
no 21 (84%) 5 (83.3%) 16 (84.3%)
Bone-targeted agents [no (%)]
Yes 4 (16%) 1 (16.7%) 3 (15.7%)
no 21 (84%) 5 (83.3%) 16 (84.3%)
Median biochemical values (range)
Hemoglobin (g/dL) 12 13.3 10.6
albumin (g/L) 40 43 39
Lactate dehydrogenase (u/L) 315 290 320
PSa (μg/L) 79.9 (9–4,560) 30.3 (9–80) 123 (7.6–4,560)
Median injection of radium-223 6 6 5
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PSA, prostate-specific antigen; VAS, visual analog scale.
approved drugs such as abiraterone acetate, enzalutamide, 
and cabazitaxel, with 24% of the men treated with four lines 
of therapy. These data may reflect a more aggressive disease 
and explain the lower OS of our patients. Interestingly, 
we observed a statistically significant advantage in OS for 
patients with VAS ,4 compared to other patients (12.6 vs 
6.6 months), in particular, in the group of VAS ,4, the OS 
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pain is a multifactorial parameter, there is a strict correlation 
with tumor burden on one side and with survival on the other. 
In addition, pain is a statistically significant predictor of OS 
in men with metastatic CRPC with bone metastases.8 In fact, 
men with minimal symptoms have prolonged survival.9 These 
data were all confirmed in the men treated with radium-223.
Although radium-223 is approved by the FDA in 2013, 
studies with high levels of evidence on the optimal sequence 
of its administration among all other approved treatments 
for CRPC are lacking. In addition, the ALSYMPCA study 
had a main limitation of the absence of patients previously 
or concomitantly treated with new hormonal therapies, such 
as abiraterone or enzalutamide. Recently, a single-arm Phase 
III-b trial conducted to enable early access to radium-223 
included patients concomitantly treated with a novel hor-
monal therapy.10 It showed results quite similar to those of 
the ALSYMPCA trial, with a longer OS in patients concomi-
tantly treated with a novel hormonal therapy compared to 
those without. However, the European Medicines Agency 
announced at the Pharmacovigilance Risk Assessment 
Committee meeting conducted from 27 to 30 November, 
2017, that there was an increased risk of death and frac-
tures reported in an ongoing clinical trial of prostate cancer 
medicine on comparing radium-223 with placebo, both 
administered in combination with abiraterone acetate and 
prednisone/prednisolone.11
Conclusion
The present study suggests a possible effect of radium-223 
on the OS of CRPC with VAS ,4 and also in heavily pre-
treated patients for whom data are lacking. Unfortunately, 
the present study had several limitations, including a small 
number of evaluated patients and the retrospective nature of 
the data. Therefore, prospective large-scale trials are neces-
sary to evaluate the role of radium-223 in the sequence of 
treatment of metastatic CRPC.
Disclosure
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aLP rr .30% 9 (36%) 2 (33.3%) 7 (36.8%) 0.6
Radiological response
SD 12 (48%) 2 (33.3%) 10 (52.6%) 0.3
PD 13 (52%) 4 (66.7%) 9 (47.4%)
Pre-radium-223
analog scale 





for pain (VaS 
pain; median)
3 1.5 3
Abbreviations: PD, progressive disease; rr, response rate; SD, stable disease; VaS, 
visual analog scale.
Figure 2 Median VaS before and post-radium-223 according to initial VaS.
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